5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency.

[1]  E. Gamelin,et al.  Tumor quantification of several fluoropyrimidines resistance gene expression with a unique quantitative RT-PCR method. Implications for pretherapeutic determination of tumor resistance phenotype. AUTHORS , 2003 .

[2]  R. Diasio,et al.  The Uracil Breath Test in the Assessment of Dihydropyrimidine Dehydrogenase Activity: Pharmacokinetic Relationship between Expired 13CO2 and Plasma [2-13C]Dihydrouracil , 2006, Clinical Cancer Research.

[3]  E. Gamelin,et al.  An accurate dihydrouracil/uracil determination using improved high performance liquid chromatography method for preventing fluoropyrimidines-related toxicity in clinical practice. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[4]  E. Gamelin,et al.  Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity , 2004, Clinical Cancer Research.

[5]  Hao Jiang,et al.  Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels , 2004, British journal of pharmacology.

[6]  Marc Buyse,et al.  Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  A. B. Kuilenburg,et al.  Pharmacogenetic and clinical aspects of dihydropyrimidine dehydrogenase deficiency , 2003 .

[8]  A. V. van Kuilenburg,et al.  Increased risk of grade IV neutropenia after administration of 5‐fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: High prevalence of the IVS14+1g>a mutation , 2002, International journal of cancer.

[9]  Martin R. Johnson,et al.  A comparative analysis of translated dihydropyrimidine dehydrogenase cDNA; conservation of functional domains and relevance to genetic polymorphisms. , 2002, Pharmacogenetics.

[10]  F. Baas,et al.  Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  P. Vreken,et al.  Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  S. J. Johnston,et al.  Cloning and initial characterization of the human DPYD gene promoter. , 2000, Biochemical and biophysical research communications.

[13]  H. McLeod,et al.  Known variant DPYD alleles do not explain DPD deficiency in cancer patients. , 2000, Pharmacogenetics.

[14]  Martin R. Johnson,et al.  Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Robert,et al.  Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Vreken,et al.  Nomenclature for human DPYD alleles. , 1998, Pharmacogenetics.

[17]  H. Togari,et al.  Identification of novel mutations in the dihydropyrimidine dehydrogenase gene in a Japanese patient with 5-fluorouracil toxicity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[18]  J. Robert,et al.  Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Vreken,et al.  Dihydropyrimidine dehydrogenase (DPD) deficiency: identification and expression of missense mutations C29R, R886H and R235W , 1997, Human Genetics.

[20]  Martin R. Johnson,et al.  Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity. Screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[21]  E. Gamelin,et al.  Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[22]  P. Vreken,et al.  Identification of a four-base deletion (delTCAT296–299) in the dihydropyrimidine dehydrogenase gene with variable clinical expression , 1997, Human Genetics.

[23]  P. Rougier,et al.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  E. Gamelin,et al.  Relationship between 5‐fluorouracil (5‐FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5‐FU , 1996, Cancer.

[25]  O. Dassonville,et al.  [Population study of dihydropyrimidine dehydrogenase in cancer patients]. , 1994, Bulletin du cancer.

[26]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. , 1993, Cancer research.

[27]  F. Demard,et al.  Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. , 1992, Cancer research.

[28]  F. Gabreëls,et al.  Dihydropyrimidine dehydrogenase deficiency Neurological aspects , 1987, Journal of the Neurological Sciences.

[29]  M. Tuchman,et al.  Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity. , 1985, The New England journal of medicine.

[30]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. , 2004, Clinical colorectal cancer.

[31]  Mostafa Ronaghi.  Pyrosequencing Sheds Light on DNA Sequencing , 2001 .

[32]  U Hammerling,et al.  Determination of single-nucleotide polymorphisms by real-time pyrophosphate DNA sequencing. , 2000, Genome research.

[33]  R. Diasio,et al.  Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. , 1988, The Journal of clinical investigation.

[34]  Gerald L. Hawk,et al.  Biological Biomedical Applications of Liquid Chromatography , 1979 .